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doi:10.1016/j.ejvs.2010.09.019Abstract Introduction: We have modified the arteriovenous groin loop procedure and
present a technique associated with good patency rates and low infection rates.
Methods: We describe an alternative femoro-femoral arteriovenous loop technique which
utilises the mid-thigh sub-sartorial Superficial Femoral Artery and Femoral Vein. We then per-
formed a retrospective analysis of all such cases performed in our unit to date and analysed
the patency and infection rates associated with the technique.
Results: 16 cases have been performed to date with a median follow-up of 18 months. The
primary and secondary patency rates at one year were 70% and 90% respectively. The overall
infection rate was only 12.5%.
Conclusions: Our technique is associated with good patency rates and low infection rates. In
addition it preserves modesty whilst on dialysis and the groin vessels for further vascular
access surgery if needed.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Definitive vascular access for haemodialysis remains a key
requisite for the treatment of patients with end-stage renal
failure (ESRF). In theUK, 45,484 patientswere on established
renal replacement therapy (RRT) at the end of 2007,1 a figure
that will rise given that the current annual growth rate in the
UK of RRT is around 5%.1 The provision of permanent vascularrg.uk (J.A. Gilbert).
ty for Vascular Surgery. Publisheaccess presents an ever-increasing challenge to the vascular
access surgeon. This is in part due to the rapidly expanding
dialysis dependant population,1,2 an increase in the numbers
of elderly and diabetic patients offered RRT and prolonged
patient survival rates whilst on dialysis.3 In addition the
numbers of patients opting to commence RRT on peritoneal
dialysis is contracting.1
Autologous vein arteriovenous fistulae (AVF) remain the
vascular access of choice in patients who require long term
haemodialysis. This is due to the association with superior
long term primary patency rates and lower complication
rates including infection.4,5 There are, however, high
primary failure rates ranging between 11 and 30%6,7 and thed by Elsevier Ltd. All rights reserved.
Good Long Term Patency Rates 567time taken for maturation may vary from 6 weeks8 to 4
months.2 Prosthetic grafts, which have lower rates of
primary failure and can be used more rapidly for haemo-
dialysis,9 are generally reserved for cases where there is an
absence of suitable autologous vein. The upper extremities
tend to be used first but if access is impossible it has been
standard practice to then construct a femoro-femoral
arteriovenous loop graft. Polytetrafluoroethylene (PTFE)
has generally been used but, unfortunately, infection rates
are high.10 In addition, patency rates are poorer11,12 and
more frequent revision surgery is required.11
We have modified the groin loop procedure and present
an alternative femoro-femoral arteriovenous loop graft
technique. A similar modified technique was described by
Bagul et al. in 200613 but our technique and the graft we
use are different and in our experience, associated with
low infection rates and good patency. We therefore present
our current series of adductor loop grafts and report the
time to needling, infection and patency rates.Figure 1 Artist impression of surgical dissection demon-
strating mid-thigh sub-sartorial Superficial femoral artery (SFA)
and superficial femoral vein (SFV).The Adductor Loop Technique
Any patient in our unit requiring vascular access for hae-
modialysis, in whom all upper limb options had been
exhausted or were not possible, were considered for the
adductor loop technique. Our unit has no experience of
thoracic grafts and the femoral vein transposition tech-
nique was not favoured due to problems with venous
hypertension and low success rates in the very small
numbers attempted. All patients who were considered for
an adductor loop graft underwent pre-operative venous and
arterial duplex imaging. We don’t routinely perform an
Ankle Brachial Pressure Index (ABPI) measurement, espe-
cially in diabetics, as the result is generally misleading due
to the lack of compressibility of calcified ankle vessels. The
arterial system is imaged to ensure that there is biphasic
waveform flow to the ankle, signifying healthy vessels
capable of delivering good inflow to the graft whilst main-
taining distal perfusion so as to avoid ischaemia or a steal
syndrome postoperatively. The venous system of the leg is
imaged to ensure compressibility and patency with no
underlying venous thrombosis that would affect the outflow
of the graft. The graft is always placed on the side of any
previous transplant to spare the contra-lateral side for
future transplantation. This ensures that the venous pres-
sure is normal on the side of future transplantation and
minimises the risk of arteriovenous graft thrombosis when
clamping the iliac vessels to implant a kidney.
To date, all of our cases have been performed under
general anaesthetic. Patients are given a 300 mg loading
dose of Aspirin pre-operatively if not already on it. Prophy-
lactic antibiotics (1.2 g Co-amoxiclav and 1 g Vancomycin
intravenously) are given at induction. The patient is posi-
tioned supinewith the operative leg flexed at the knee and in
abduction (frog-legged) so as to access themedial side of the
thigh. An 8e10 cm incision is placed on the medial aspect of
the mid-thigh over the anterior border of Sartorius muscle
and dissection between Sartorius and the medial edge of
Vastus Medialis is performed to expose the sub-sartorial mid-
thigh femoral vein and superficial femoral artery (SFA)
(Fig. 1). The vessels aremobilised and controlled. As the veinlies deep to the artery, additional arterial mobilisation is
often required in both a caudal and a cephalad direction to
enable adequate exposure of the vein. A vertical incision
2e3 cm in length, in a caudal-cranial direction is then made
as laterally as possible (Fig. 2 e labelled ‘counter incision’)
down to fascia lata to enable creation of the subcutaneous
tunnel. A non-sheathed vascular tunnelling device is used in
a two staged technique utilising both incisions. This involves
bringing the arterial end of the graft from themedial incision
out to the lateral ‘counter incision’ and then bringing the
graft from the lateral incision back to the medial incision so
as to ensure a nice curve on the graft. A 6 mm diameter,
40 cm long Bard PTFE Venaflo graft is placed in a transverse
loop position (Fig. 2) in the superficial fat just beneath the
skin. There is approximately 25 cm of the graft forming the
loop that is easily accessible for needling for subsequent
haemodialysis. The venous outflow end of the graft lies
distally. This ensures that the venous hood of the graft is in
a position to ensure in line flow from the graft into the native
femoral vein in an attempt tomaximise smooth laminar flow.
This hopefully reduces the development of local myointimal
hyperplasia and subsequent venous stenoses. The arterial
and venous anastomoses are performed using 6.0 poly-
propylene. The venotomy is made as long as possible to
utilise the entire length of the flared end of the Bard PTFE
Venaflo graft. The facial layer is closedwith 2.0 polyglactin
910 and the skin is closed with interrupted 3.0 polypropylene
horizontalmattress sutures. Post-operative stay is one to two
days. The commonest complication is localised swelling at
the site of tunnelling. This has usually settled by two weeks.
Patients are discharged on 75 mg Aspirin daily, if not already
on it, to continue indefinitely. Follow-up is by the vascular
access nurse specialist at 2 weeks. Haemodialysis is avoided
until all wounds are healed and the swelling has settled, but
not before 2 weeks.
Results
Since introducing the adductor loop technique in early 2006,
wehaveperformed16 cases over 4 years. All patientswere on
established haemodialysis prior to procedure. 11 of the grafts
Figure 2 Artist impression of positioned Venoflo graft with
site of ‘counter incision’ to allow graft tunnelling.
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were diabetic (male: femaleZ 4:1). A total of 9 right sided
loop grafts and 7 left sided loop grafts have been formed. The
mean age was 55 years with a range of 27e72 years. The
median follow-up for the 16 caseswas 18months. Themedian
time to needling was 31 days (range 12e583 days).
All 16 cases had primary function and worked immedi-
ately. Thirteen of the 16 grafts have been in follow-up for
more than 12 months. At 6 months, the primary patency
rate was 81.8% (9/11). The secondary patency rate was
100% (11/11) as 2 cases underwent successful thrombec-
tomy. One graft had to be ligated at 2 months for high
output cardiac failure and one patient died at 4 months
with a functioning graft.
The primary patency rate at one year was 70% (7/10). The
one year secondary patency was 90% (9/10) as 1 case under-
went successful thrombectomyat10months andonegrafthad
thrombosed at 7 months shortly after a successful transplant.
One patient died at 7 months with a functioning graft.
Two (12.5%) patients were treated for infective
complications during the first year. One episode occurred
within the first 5 days. This may have been a combination of
swelling and erythema from the tunnelling of the graft
rather than actual infection. Nonetheless it was treated as
an infection and has been analysed as such. The remaining
infection was over a needling site and occurred at day 305.
It was associated with graft thrombosis which underwent
successful thrombectomy. Neither patient was a diabetic.
The 3 cases that have not been included in the analysis
were all formed within the last 6 months without compli-
cation and remain patent.
The 9 grafts that were patent at one year had median
pump speeds of 400 ml/min (range 250e450 ml/min) on
haemodialysis. Transonic measurements of flow in the 9
grafts at one year demonstrated median flow rates of
1395 ml per minute, a figure highly supportive of excellent
flow in the grafts which can provide high quality
haemodialysis.
Discussion
The mid-thigh adductor loop arteriovenous graft has been
previously described13e15 but we believe that our techniqueand the graft we use may provide additional benefits in
improving the longer term patency rates. Vascular access is
becoming increasingly more challenging and demanding to
the vascular access surgeon particularly given that more
patients start renal replacement therapy on haemodialysis.1
The National Kidney Foundation Dialysis Outcomes Quality
Initiative (NKFDOQI) guidelines recommend that permanent
vascular access is constructed within a year of anticipated
need for dialysis.16 In striving to meet these targets in the
increasing numbers of patients who need vascular access,
there is now a growing population of haemodialysis patients
who require tertiary access procedures. Many of these
patients exhaust all autologous vein options very quickly and
therefore require a prosthetic graft. Initially this can be
placed in the upper limb but over time, significant propor-
tions of patients require a femoro-femoral arteriovenous
fistula or graft in the groin or thigh. The PTFE arteriovenous
graft is the commonest type of vascular access created in the
thigh and has patency and complication rates comparable to
those of upper arm PTFE grafts.17 The patency rates are
generally poor especially when compared with autologous
vein fistulae (58% vs 72% at six months and 33% vs 51% at 18
months in a recent meta-analysis).12 In our series we had
primary and secondary patency rates of 81.8% and 100% at 6
months and 70% and 90% at 1 year. Our ongoing primary and
secondary patency rates continue to remain high at 18
months and 2 years (Table 1) and are rates that are higher
than those previously quoted in the literature.15,18 The
recently published data by Scott et al.15 reported on a series
of 46mid-thigh loop grafts placed in 38 patients over a 3 year
period. Their reported primary and secondary patency rates
were 40% and 68% at one year and 18% and 43% at two years.
Whilstweaccept that thenumbers in our series are small, it is
our view, that the use of the Bard Venaflo graft and our
technique of placing the graft that contributes to our very
good patency rates. It is now recognised that an expanded
distal end of PTFE at the venous anastamosis, as is the case
with the Venaflo graft, improves patency.19 We favour the
Venaflo graft over uncuffed grafts due to our unpublished
work showing a doubling of primary patency rates associated
with Venaflo. Careful positioning and placement of the
graft can further improve patency. The technique we
describe involves ensuring that the venous end of the graft is
in a position to ensure in line flow from the graft into the
native femoral vein in a way that would mirror native
anatomical venous drainage. This minimises the degree of
low shear associated with increased turbulence and stag-
nated flow within the venous hood thereby minimising the
degree of myointimal hyperplasia and subsequent venous
stenosis.19,20
The reported infection rates associated with PTFE grafts
varies from 9% to 30% per annum.11,21,22 Our reported
infection rate within the first year was no more than 12.5%
(2/16 grafts) and is probably lower as one of these grafts
was probably not infected but had swelling and erythema
from the tunnelling process. This compares favourable with
the reported infection rates in the Scott et al.15 series
where infection rates were 21% and requiring graft
removal. It is our view that in moving the PTFE graft
a significant distance from the groin to the mid-thigh may
be one of the factors associated with a more favourable
infection rate.
Table 1 Two year primary and secondary patency rates (graft numbers in brackets).
Time after Graft formed Primary Patency Rates Secondary Patency Rates
3 Months 100% (13/13) 100% (13/13)
6 Months 81.8% (9/11) 100% (11/11)
9 Months 80% (8/10) 90% (9/10)
12 Months 70% (7/10) 90% (9/10)
15 Months 70% (7/10) 90% (9/10)
18 Months 70% (7/10) 80% (8/10)
21 Months 62.5% (5/8) 75% (6/8)
24 Months 62/5% (5/8) 75% (6/8)
Good Long Term Patency Rates 569In addition to the favourable patency and infection rates
associated with our technique, it preserves modesty whilst
on dialysis and preserves both the lymph node bearing
tissues in the groin and the groin vessels for further vascular
access surgery if needed.Acknowledgements
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